Flyte Aviation Inc. (VJET) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Flyte Aviation Inc. (NYSE: VJET) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $0.59 (-9.02% 1D, market cap $1.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, VJET ranks #421 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), VJET carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of 92.3%, and ROIC of -35.0%. By comparison, PFSA (Profusa Inc.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -35.0%, cap $466.9K) and NXGL (NexGel Inc) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $1.9M). Among the 5-stock peer group, VJET leads on earnings multiple (N/A) while VJET leads on capital efficiency (-35.0% ROIC).
Per VJET's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001716621), Flyte Aviation Inc. generated $819.0K in revenue (+95.0% YoY), -$17.2M in net income, and -$8.3M in free cash flow against $15.9M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 27.2 (OVERSOLD (<32))
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While VJET currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Big institutional funds and options desks are actively positioning on the bullish side.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.40) and Max Pain ($0.62) forces dealer call-delta covering toward $32.13.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Flyte Aviation Inc. (VJET) dropped -9.02% to $0.59, trading at 2% of its 52-week range ($0.58 – $30.6). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Cross-border Canadian Flights Inaugurate New International MarketFlyte’s Growing U.S. Aviation Network Now Connected to Major DestinationsAdvances Flyte’s Tech-Driven Private Aviation Network Across North America NEW YOR
Flyte Aviation, Inc. (NYSE American: VJET) ("Flyte" or the "Company"), a technology-enabled private aviation company, today announced that it has received approval from Transport Canada, the department
Flyte Intends to Double Its Vision Jet Fleet to Ten Aircraft in the First Quarter of 2027, Further Expanding Regional Private Aviation Capacity and Footprint All Flyte Vision Jets for Charter are equipped with the Garmin
FORT MILL, S.C, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, a wholly owned subsidiary of Flyte Aviation, Inc. (NYSE American: VJET), today announced the first published comparative study evaluating its LockeT s
Catheter Precision, a wholly owned subsidiary of Flyte Aviation, Inc. (NYSE:VJET), today announced the first published comparative study evaluating its LockeT suture retention device against a traditional internal
New Digital Platform Provides Strategic Partners with Dedicated Accounts, Streamlined Booking and Exclusive Preferred Partner PricingLaunch Transforms Flyte’s Growing Network of Partnerships Across Hospitality, Sports, E
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +95.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on VJET today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for VJET. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Flyte Aviation Inc. (VJET) ranks #421 by composite RQD confidence (45/100, grade D) and #1012 by equity capitalization ($1.4M). Within this direct 5-issuer industry benchmark cohort, VJET leads on earnings valuation at N/A trailing P/E, while VJET leads on capital efficiency and profitability with -35.0% ROIC and 92.3% gross margin. PFSA currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with VJET at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| VJET
ACTIVE
Flyte Aviation Inc. | D | 45/100 | — | 92.3% | -35.0% | -9.02% | $1.4M | Benchmark Subject |
| PFSA Profusa Inc. | D+ | 52/100 | — | — | -35.0% | -9.18% | $466.9K | /pfsa-vs-vjet → |
| NXGL NexGel Inc | E | 28/100 | — | 39.5% | -35.0% | -9.54% | $1.9M | /nxgl-vs-vjet → |
| BJDX Bluejay Diagnostics Inc. | D- | 38/100 | — | — | -35.0% | +2.98% | $2.4M | /bjdx-vs-vjet → |
| IVF INVO Fertility Inc. | D- | 35/100 | — | 96.0% | -35.0% | -10.93% | $2.5M | /ivf-vs-vjet → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Flyte Aviation Inc. (VJET) reported GAAP revenue of $819.0K (+95.0% vs. FY2024 revenue of $420.0K , and +85.3% cumulative change since FY2023) , GAAP net income of -$17.2M, operating cash flow of -$8.3M, and free cash flow of -$8.3M (+11.0% YoY). On the balance sheet, VJET closed FY2025 with $15.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $819.0K | -$17.2M | -$8.3M | -$8.3M | $15.9M | — |
| FY2024 (FY) | 2024-12-31 | $420.0K | -$16.6M | -$9.3M | -$9.3M | $27.8M | — |
| FY2023 (FY) | 2023-12-31 | $442.0K | -$70.6M | -$20.6M | -$20.6M | — | — |
As of 2026-11-02, Flyte Aviation Inc. (NYSE: VJET) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $0.59 (-9.02% 1D, market cap $1.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, VJET ranks #421 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), VJET carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of 92.3%, and ROIC of -35.0%. By comparison, PFSA (Profusa Inc.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -35.0%, cap $466.9K) and NXGL (NexGel Inc) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $1.9M). Among the 5-stock peer group, VJET leads on earnings multiple (N/A) while VJET leads on capital efficiency (-35.0% ROIC).
Per VJET's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001716621), Flyte Aviation Inc. generated $819.0K in revenue (+95.0% YoY), -$17.2M in net income, and -$8.3M in free cash flow against $15.9M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
VJET last traded at $0.59 (-9.02% on volume of 77,182 shares), positioning the stock -57.86% below its 50-day simple moving average ($1.40) and -92.96% below its 200-day simple moving average ($8.38). Across its 52-week range of $0.58 to $30.60, VJET sits at the 0.0% percentile with a 14-day RSI of 27.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.66).
Why VJET Stock dropped -9.02% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).